Home Biosimilar Antibodies Others CD markers Itolizumab (Anti-CD6)
For research use only. Not for use in humans.

Itolizumab (Anti-CD6)

Synonyms: FRP-1， SLC3A2

Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD.

Itolizumab (Anti-CD6)

Quality Control

Batch: A255201 Purity: 99% Protein concentration: 12.76mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD.

Product Details

CAS No. 1116433-11-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07395050 NOT_YET_RECRUITING Drug: AutoCD6-CAR Treg cells Stage 3 Type 1 Diabetes City of Hope Medical Center 2026-09-01 EARLY_PHASE1
NCT05978544 UNKNOWN Drug: Itolizumab Acute Respiratory Distress Syndrome Biotech Pharmaceutical Co., Ltd. 2023-12-31 PHASE1
NCT05986162 UNKNOWN Drug: Itolizumab Dermatomyositis, Adult Type Biotech Pharmaceutical Co., Ltd. 2023-12-30 PHASE1
NCT05263999 TERMINATED Drug: EQ001 Placebo Graft Versus Host Disease; GVHD; Acute-graft-versus-host Disease; Acute GVHD; aGVHD Equillium 2022-04-29 PHASE3
NCT05823675 UNKNOWN Drug: Itolizumab|Drug: Methylprednisolone Acute Graft Versus Host Disease Biotech Pharmaceutical Co., Ltd. 2023-05-19 PHASE1
NCT04128579 COMPLETED Drug: Itolizumab [Bmab 600] Lupus Erythematosus; Lupus Nephritis Biocon Limited 2019-10-01 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.